-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that BeiGene's PD-1 antibody drug Bezeran (Tilelizumab) has been in the "approval" stage for two new indications (acceptance number: CXSS2000032, CXSS2000033).
The two indications to be approved this time are: 1) Combined chemotherapy for the treatment of patients with first-line advanced non-squamous non-small cell lung cancer (NSCLC)
An open, multi-center, randomized phase III clinical trial code-named RATIONALE 304 evaluated the combination of pemetrexed with pemetrexed and platinum-based chemotherapy drugs (carboplatin or cisplatin), compared with pemetrexed and platinum only Class chemotherapeutics, curative effect in the treatment of first-line stage IIIB or IV non-squamous NSCLC patients
As of the data cut-off point of January 23, 2020, the median follow-up time was 9.
A pivotal phase II clinical trial (NCT03419897) evaluated the efficacy of Bezan in the treatment of unresectable HCC patients who had previously received treatment
Attached table: PD1/PD-L1 domestic application for listing and approval
Attached table: PD1/PD-L1 domestic application for listing and approval